Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CCR2 | P41597 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200769 | 0.92 | METAP2 (0.71) | METAP2KDM4ELMNATP53MAPT | |
| SCHEMBL12570805 | 0.91 | METAP2 (0.86) | METAP2LMNAHTTCYP1A2CYP2C9 | |
| SCHEMBL2009251 | 0.87 | METAP2 (1.00) | METAP2LMNAHTTCYP1A2CYP2C9 | |
| SCHEMBL13484207 | 0.87 | LMNA (0.72) | METAP2LMNATP53MAPTHTT | |
| SCHEMBL491833 | 0.86 | METAP2 (1.00) | METAP2LMNATP53MAPTHTT | |
| SCHEMBL7322109 | 0.84 | METAP2 (0.73) | METAP2KDM4ELMNATP53HTT | |
| SCHEMBL23200296 | 0.83 | MCL1 (0.66) | METAP2KDM4ELMNATP53MAPT | |
| SCHEMBL16496289 | 0.83 | METAP2 (0.75) | METAP2LMNAHTTCYP1A2CYP2C9 | |
| SCHEMBL3984413 | 0.83 | METAP2 (1.00) | METAP2KDM4E | |
| SCHEMBL4097689 | 0.83 | METAP2 (0.66) | METAP2KDM4EKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960435-B2 | Anti-cancer agents and androgen inhibition activity compound | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2008076918-A9 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIV MARYLAND (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008076918-A2 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113600-A1 | ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND | AR, HTR3D, NR5A1 | METAP2 3615/4885KDM4E 2138/4885LMNA 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.